npj Breast Cancer

Papers
(The median citation count of npj Breast Cancer is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers496
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer251
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab192
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment165
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors118
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer117
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab102
Immunotherapy for early triple negative breast cancer: research agenda for the next decade95
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer89
Biological correlates associated with high-risk breast cancer patients identified using a computational method88
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer83
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer83
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells73
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients73
International survey on invasive lobular breast cancer identifies priority research questions66
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial63
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC61
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer55
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events55
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays53
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines52
Breastfeeding attributable fraction of triple negative breast cancer in the US50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer50
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer48
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice48
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer47
Temporal evolution of breast cancer brain metastases treatments and outcomes45
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer42
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)41
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer40
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models40
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions40
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)38
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases37
Survival outcomes after omission of surgery for ductal carcinoma in situ35
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer34
Circulating tumor DNA validity and potential uses in metastatic breast cancer34
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature34
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center33
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification32
Understanding metastasis mixed-treatment responses through genomic analyses32
Kataegis in clinical and molecular subgroups of primary breast cancer32
Is conservative management of ductal carcinoma in situ risky?32
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer32
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling32
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment31
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201630
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models30
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer30
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors30
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment29
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer29
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance29
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer29
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program29
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer27
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin26
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 26
Large language model (ChatGPT) as a support tool for breast tumor board26
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies26
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer25
Cook and Move for Your Life, an eHealth intervention for women with breast cancer25
A systematic review of determinants of breast cancer risk among women with benign breast disease24
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy24
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer23
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models22
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer22
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer22
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis22
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies22
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers21
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer21
Prognostic value of structural variants in early breast cancer patients21
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis21
Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history21
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer20
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women20
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study20
Evaluating mammographic density′s contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors19
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation19
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer19
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence19
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape18
Subclonal heterogeneity and evolution in breast cancer18
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy18
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women18
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer17
Author Correction: Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer17
Racial discrimination among women seeking breast cancer care17
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study17
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer17
Plasma C-peptide mammographic features and risk of breast cancer17
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy17
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention17
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer16
Artificial intelligence in breast pathology – dawn of a new era16
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib16
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer16
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer16
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer16
Post-diagnosis weight trajectories and mortality among women with breast cancer16
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study16
Proteogenomic characterization of invasive breast tumors in young women16
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts16
Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer16
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer15
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
Advancing equitable access to innovation in breast cancer15
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study15
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings15
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial15
Genomic landscapes of breast cancer in African populations: a systematic review15
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer15
Genomic landscape of breast cancer in elderly patients15
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials14
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer14
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer14
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery14
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study14
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer14
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer14
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer14
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials13
Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer13
An emerging generation of endocrine therapies in breast cancer: a clinical perspective13
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer13
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease13
Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer13
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients13
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers13
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR13
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management13
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer13
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function13
Bridging the gap: ctDNA, genomics, and equity in breast cancer care13
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment13
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy13
Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation13
Computerized cognitive training improves cognitive function in primary breast cancer survivors13
De-escalation in breast cancer surgery13
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden13
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers12
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning12
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer12
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer12
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial12
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer12
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ12
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade12
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study12
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools12
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients12
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning11
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab11
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer11
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer11
The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer11
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer11
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis11
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis11
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research10
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer10
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes10
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes10
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)10
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death10
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial10
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer10
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer10
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer10
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment10
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study10
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis10
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy10
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study10
Allostatic load as a predictor of postoperative complications in patients with breast cancer10
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial10
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients9
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling9
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer9
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis9
CBD-oil as a potential solution in case of severe tamoxifen-related side effects9
Modeling tumor relapse using proliferation tracing and ablation transgenic mouse9
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing9
Mammographic texture features associated with contralateral breast cancer in the WECARE Study9
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study9
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy9
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer9
Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer9
Author Correction: Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing9
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets8
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer8
Predicting pathologic ≥N2 disease in women with breast cancer8
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer8
Immunotherapy in breast cancer: an overview of current strategies and perspectives8
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer8
Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives8
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC8
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study8
Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP)8
The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue8
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies8
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer7
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis7
NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer7
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy7
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models7
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors7
Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer7
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib7
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy7
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype7
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer7
Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis7
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer6
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 405026
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets6
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer6
Integrative multiomics-histopathology analysis for breast cancer classification6
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)6
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer6
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer6
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial6
Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trial6
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness6
Immune landscape of breast tumors with low and intermediate estrogen receptor expression6
Triple negative breast cancer: Pitfalls and progress6
Reversion of breast epithelial polarity alterations caused by obesity6
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial6
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey6
Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer6
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ6
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer6
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)6
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer6
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer6
0.070243120193481